Study | Drug | Subjects, N | Male (%) | Mean age, years (SD) | Mean % predicted FEV1 (SD) | Treatment duration, weeks |
---|---|---|---|---|---|---|
Asai et al. (2015) [17] | SFC 50/250 µg, bid | 26 | 25 (96) | 64.7 (9.31) | 1.983 (0.5797) | 12 |
 | Placebo | 26 | 26 (100) | 62.2 (8.06) | 2.044 (0.4638) |  |
Zhong et al. (2015) [22] | QVA149 110/50 μg, qd | 372 | 341 (91.7) | 64.8 (7.8) | 51.6 (12.8) | 26 |
 | SFC 50/500 μg, bid | 369 | 331 (89.7) | 65.3 (7.9) | 52.0 (12.9) |  |
Bhatt et al. (2017) [15] | FF/VI 100/25 μg, qd | 141 | 104 (77) | 68.5 (8.0) | 1.29 (0.43) | 24 |
 | VI 25 μg, qd | 158 | 118 (77) | 68.7 (7.7) | 1.24 (0.42) |  |
 | Placebo | 145 | 119 (84) | 68.2 (8.1) | 1.30 (0.44) |  |
Dransfield et al. (2013) [16] | VI, 25 μg, qd | 818 | 474 (58) | 63·6 (9·4) | 1·3 (0·5) | 52 |
 | FF/VI 50/25 µg, qd | 820 | 476 (58) | 63·6 (9·4) | 1·3 (0·5) |  |
 | FF/VI 100/25 μg, qd | 806 | 453 (56) | 63·8 (9·2) | 1·3 (0·5) |  |
 | FF/VI 200/25 µg, qd | 811 | 467 (57) | 63.7 (9.0) | 1·3 (0·5) |  |
Kerwin et al. (2013) [23] | FF 100 μg, qd | 206 | 132 (64) | 62.7 (9.47) | 46.9 (12.73) | 24 |
 | VI 25 μg, qd | 205 | 140 (68) | 63.4 (9.58) | 49.9 (12.05) |  |
 | FF/VI 50/25 μg, qd | 206 | 135 (66) | 62.8 (9.13) | 48.4 (12.66) |  |
 | FF/VI 100/25 μg, qd | 206 | 137 (67) | 62.3 (8.49) | 47.8 (12.28) |  |
 | Placebo | 207 | 141 (68) | 62.1 (8.80) | 48.5 (12.46) |  |
Maltais et al. (2002) [24] | BUD 2Â mg q6h | 71 | 57 (80.2) | 69.1 (8.7) | 1.14 (0.45) | 1.5 |
 | Placebo | 66 | 53 (80.3) | 70.4 (8.9) | 1.13 (0.44) |  |
Martinez et al. (2013) [25] | FF 100 μg, qd | 204 | 150 (74) | 61.8 (8.28) | 48.4 (12.17) | 24 |
 | FF 200 μg, qd | 203 | 151 (74) | 61.8 (9.02) | 47.1 (11.98) |  |
 | VI 25 μg, qd | 203 | 151 (74) | 61.2 (8.62) | 48.5 (12.89) |  |
 | FF/VI 100/25 μg, qd | 204 | 144 (71) | 61.9 (8.79) | 48.1 (12.85) |  |
 | FF/VI 200/25 μg, qd | 205 | 137 (67) | 61.1 (8.58) | 47.1 (12.76) |  |
 | Placebo | 205 | 152 (74) | 61.9 (8.14) | 48.3 (12.71) |  |
Sharafkhaneh et al. (2012) [26] | BUD/FM 320/9 μg bid | 407 | 262 (64.4) | 63.8 (9.4) | 37.9 (11.8) | 48 |
 | BUD/FM 160/9 μg bid | 408 | 264 (64.7) | 62.8 (9.2) | 37.6 (11.6) |  |
 | FM 9 μg bid | 403 | 229 (56.8) | 62.5 (9.4) | 37.5 (12.4) |  |
Siler et al. (2016) [27] | FF/VI 100/25 μg, qd | 806 | 605 (75) | 65.3 (8.58) | 50.3 (10.33) | 12 |
 | VI 25 μg, qd | 814 | 625 (77) | 65.4 (9.02) | 50.5 (10.33) |  |
Vogelmeier et al. (2013) [28] | QVA149 110/50 μg, qd | 258 | 181 (70.2) | 63·2 (8·2) | 60·5 (10·5) | 26 |
 | SFC 50/500 μg, bid | 264 | 189 (71.6) | 63·4 (7·7) | 60·0 (10·7) |  |
Vestbo et al. (2016) [29] | FF 100 μg, qd | 4157 | 3053 (73.8) | 65 (8) | 59·6 (6·1) | 96 |
 | VI 25 μg, qd | 4140 | 3053 (74.1) | 65 (8) | 59·7 (6·1) |  |
 | FF/VI 100/25 μg, qd | 4140 | 3112 (75.5) | 65 (8) | 59·7 (6·1) |  |
 | Placebo | 4131 | 3071 (74.7) | 65 (8) | 59·7 (6·1) |  |
Wedzicha et al. (2014) [30] | BDP/FOR 100/6 μg × 2, bid | 601 | 408 (69) | 64.6 (8.6) | 41.9 (6.0) | 48 |
 | FOR 12 μg, bid | 596 | 410 (69) | 63.9 (8.6) | 41.6 (6.0) |  |
Zheng et al. (2014) [31] | FF/VI 50/25 μg, qd | 160 | 144 (90) | 65.2 (8.41) | 47.5 (14.21) | 24 |
 | FF/VI 100/25 μg, qd | 161 | 149 (93) | 65.1 (9.19) | 49.6 (13.19) |  |
 | FF/VI 200/25 μg, | 160 | 145 (91) | 62.7 (8.65) | 48.2 (13.63) |  |
 | Placebo | 162 | 146 (90) | 64.7 (8.78) | 48.6 (13.39) |  |
Lipson et al. (2018) [18] | FF/UMEC/VI 100/62.5/25 μg, qd | 4151 | 2766 (66.6) | 65.3 (8.2) | 45.7 (15.0) | 52 |
 | FF/VI 100/25 μg, qd | 4134 | 2748 (66.5) | 65.3 (8.3) | 45.5 (14.8) |  |
 | UMEC/VI 62.5/25 μg, qd | 2070 | 1356 (65.5) | 65.2 (8.3) | 45.4 (14.7) |  |
NCT00857766 [32] | FSC 250/50 μg, bid | 123 | 68 (55.3) | 63.6 (8.92) |  | 16 |
 | Matching Placebo | 126 | 74 (58.7) | 63.5 (7.88) |  |  |
Wedzicha et al. (2016) [19] | QVA149 110/50 μg, qd | 1678 | 1299 (77.3) | 64.6 (7.9) | 44.0 (9.5) | 52 |
 | SFC 50/500 μg, bid | 1680 | 1258 (74.8) | 64.5 (7.7) | 44.1 (9.4) |  |
NCT03474081 [33] | FF/UMEC/VI 100/62.5/25 μg, qd | 400 | 274 (68.5) | 66.2 (8.08) |  | 12 |
 | Tiotropium 18 μg, qd | 399 | 269 (67.3) | 66.1 (7.78) |  |  |